Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 5/2013

01.10.2013 | Therapy in Practice

The Management of Acne Vulgaris in Pregnancy

verfasst von: Fiona M. Meredith, Anthony D. Ormerod

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Acne vulgaris is a common condition in adolescence and also for many women of childbearing age. The management of acne in pregnancy is complicated by the lack of clinical studies and pharmacokinetic data in this patient population and safety concerns regarding retinoid use in pregnancy. Of primary concern to both patients and clinicians is the safety profile of medications used during pregnancy. This review seeks to clarify what management options are available to treat acne during pregnancy and what data are available to guide decision making. Topical treatments are considered the safest option during pregnancy. They have the best safety profile and minimize the levels of systemic absorption, and therefore the least risk of fetal exposure. If these are applied properly with a strong emphasis on adherence, excellent results can be achieved.
Literatur
1.
Smithard A, Glazebrook C, Williams HC. Acne prevalence, knowledge about acne and psychological morbidity in mid-adolescence: a community-based study. Br J Dermatol. 2001;145:274–9.PubMedCrossRef
2.
3.
Williams C, Layton AM. Persistent acne in women: implications for the patient and for therapy. Am J Clin Dermatol. 2006;7(5):281–90.PubMedCrossRef
4.
Shafer T, Nienhaus A, Vieluf D, et al. Epidemiology of acne in the general population: the risk of smoking. Br J Dermatol. 2001;145:100–4.CrossRef
5.
Burton JL, Cunliffe WJ, Stafford I, et al. The prevalence of acne vulgaris in adolescence. Br J Dermatol. 1971;85:119–26.PubMedCrossRef
6.
7.
8.
Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–63.PubMedCrossRef
9.
Nast A, Dréno B, Bettoli V, et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012;26:1–29.PubMedCrossRef
10.
Elling SV, Powell FC. Physiological changes in the skin during pregnancy. Clin Dermatol. 1997;15:35–43.PubMedCrossRef
11.
Burton JL, Cunliffe WJ, Millar DG, Shuster S. Effect of pregnancy on sebum excretion. BMJ. 1970;2:769–71.PubMedCrossRef
12.
Muzaffar F, Hussain I, Haroon TS. Physiologic skin changes during pregnancy: a study of 140 cases. Int J Dermatol. 1998;37:429–31.PubMedCrossRef
13.
Dawes M, Chowienczyk PJ. Drugs in pregnancy: pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15:819–26.PubMedCrossRef
14.
Loebstein R, Lalkin A, Koren G. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet. 1997;33:328–43.PubMedCrossRef
15.
Boothby LA, Doering PL. FDA labeling system for drugs in pregnancy. Ann Pharmacother. 2001;35:1485–9.PubMedCrossRef
16.
Public Affairs Committee of the Teratology Society. Teratology Public Affairs Committee position paper: pregnancy labeling for prescription drugs: ten years later. Birth Defects Res Part A Clin Mol Teratol. 2007;79:627–30.CrossRef
17.
Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf. 2000;23(3):245–53.PubMedCrossRef
18.
19.
20.
Tanghetti E. The evolution of benzoyl peroxide therapy. Cutis. 2008;82(5 Suppl.):5–11.PubMed
21.
Yeung D, Nacht S, Bucks D, Maibach HI. Benzoyl peroxide: percutaneous penetration and metabolic disposition. II. Effect of concentration. J Am Acad Dermatol. 1983;9:920–4.PubMedCrossRef
22.
Nacht S, Yeung D, Beasley JN, et al. Benzoyl peroxide: percutaneous penetration and metabolic disposition. J Am Acad Dermatol. 1981;4(1):31–7.PubMedCrossRef
23.
Camera G, Pregliasco P. Ear malformation in baby born to mother using tretinoin cream. Lancet. 1992;339:687.PubMedCrossRef
24.
Lipson AH, Collins C, Webster W. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet. 1993;341:1352–3.PubMedCrossRef
25.
Selcen D, Seidman S, Nigro MA. Otocerebral anomalies associated with topical tretinoin use. Brain Dev. 2000;22:218–20.PubMedCrossRef
26.
Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, et al. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother. 1998;32:505–6.PubMedCrossRef
27.
Autret E, Berjot M, Jonville-Béra A-P, et al. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet. 1997;350:339.PubMedCrossRef
28.
29.
Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341:1181–2.PubMedCrossRef
30.
Panchaud P, Csajka C, Merlob P, et al. Pregnancy outcome following exposure to topical retinoids: a multicentre prospective study. J Clin Pharmacol. 2012;52:1844–51.PubMedCrossRef
31.
Van Hoogdalem EJ. Transdermal absorption of topical anti-acne agents in man; review of clinical pharmacokinetic data. J Eur Acad Dermatol Venereol. 1998;11 Suppl. 1:S13–9.PubMedCrossRef
32.
Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure and safety. Am J Clin Dermatol. 2003;4:473–92.PubMedCrossRef
33.
Joint Formulary Committee. British National Formulary. 64th ed. London: BMJ Group and Pharmaceutical Press; 2012.
34.
Frampton JE, Wagstaff AJ. Azelaic acid 15% gel in treatment of papulopustular rosacea. Am J Clin Dermatol. 2004;5:57–64.PubMedCrossRef
35.
Täuber U, Weiss C, Matthes H. Percutaneous absorption of azelaic acid in humans. Exp Dermatol. 1992;1:176–9.PubMedCrossRef
36.
37.
Feldmann RJ, Maibach HI. Absorption of organic compounds through the skin in man. J Invest Dermatol. 1970;54:399–404.PubMedCrossRef
38.
Dreno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for acne. Eur J Dermatol. 2004;14:391–9.PubMed
39.
Harkaway KS, McGinley KJ, Foglia AN, et al. Antibiotic resistance patterns in coagulase-negative staphylococci after treatment with topical erythromycin, benzoyl peroxide, and combination therapy. Br J Dermatol. 1992;126:586–90.PubMedCrossRef
40.
Hernandez S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343:1608–14.CrossRef
41.
Hale EK, Pomeranz MK. Dermatological agents during pregnancy and lactation: an update and clinical review. Int J Dermatol. 2002;41:197–203.PubMedCrossRef
42.
Cunliffe WJ, C’otterill JA, Williamson B. The effect of clindamycin in acne: a clinical and laboratory investigation. Br J Dermatol. 1972;87:37–41.PubMedCrossRef
43.
Tan SG, Cunliffe WJ. The unwanted effects of clindamycin in acne. Br J Dermatol. 1976;94:313–5.PubMedCrossRef
44.
Owens RC, Donskey CJ, Gayens RP, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl. 1):S19–31.PubMedCrossRef
45.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
46.
Romøren M, Lindbæk M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin: a population-based register study from Norway. Br J Clin Pharmacol. 2012;74:1053–62.PubMedCrossRef
47.
Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the management of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol. 2009;60(5 Suppl.):S1–50.PubMedCrossRef
48.
Sweetman SC, et al. Martindale: the complete drug reference. 34th ed. London: Pharmaceutical Press; 2005.
49.
Kus S, Yucelten D, Aytug A. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of acne vulgaris. Clin Exp Dermatol. 2004;30:215–20.CrossRef
50.
51.
Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 1984;111:209–14.PubMedCrossRef
52.
Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol. 1986;115:227–32.PubMedCrossRef
53.
Jaussan V, Lemarchand-Beraud T, Gomez F. Modifications of the gonadal function in the adult rat after fetal exposure to spironolactone. Biol Reprod. 1985;32:1051–61.PubMedCrossRef
54.
Goodfield MJ, Cox NH, Bowser A, et al. Advice on the safe introduction and continued use of isotretinoin in acne in the U.K.: 2010. Br J Dermatol. 2010;162:1172–9.PubMedCrossRef
55.
Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med. 1985;313:837–41.PubMedCrossRef
56.
Dreno B, Blouin E. Acne, pregnant women and zinc salts: a literature review. Ann Dermatol Venereol. 2008;135(1):27–33.PubMedCrossRef
57.
Du-Thanh A, Klugr N, Bensalleh H, Guillot B. Drug-induced acneiform eruption. Am J Clin Dermatol. 2011;12:233–45.PubMedCrossRef
58.
Seukeran DC, Cunliffe WJ. The treatment of acne fulminans: a review of 25 cases. Br J Dermatol. 1999;141:307–9.PubMedCrossRef
59.
Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004;18:93–101.PubMedCrossRef
60.
61.
62.
Car J, Car M, Hamilton F, et al. Light therapies for acne (intervention protocol). Cochrane Database Syst Rev. 2009;(3):CD007917.
63.
Sakamoto FH, Torezan L, Anderson R. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol. 2010;63:195–211.PubMedCrossRef
64.
Zeichner JA. Narrowband UV-B phototherapy for the treatment of acne vulgaris during pregnancy. Arch Dermatol. 2011;147:537–9.PubMedCrossRef
65.
Cunliffe WJ, Holland DB, Clark SM, Stables GI. Comedogenesis: some new aetiological, clinical and therapeutic strategies. Br J Dermatol. 2000;142:1084–91.PubMedCrossRef
66.
Zip C. A practical guide to dermatological drug use in pregnancy. Skin Ther Lett. 2006;11:1–4.
67.
Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects. Arch Pediatr Adolesc Med. 2009;163(11):978–85.PubMedCrossRef
Metadaten
Titel
The Management of Acne Vulgaris in Pregnancy
verfasst von
Fiona M. Meredith
Anthony D. Ormerod
Publikationsdatum
01.10.2013
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 5/2013
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-013-0041-9

Weitere Artikel der Ausgabe 5/2013

American Journal of Clinical Dermatology 5/2013 Zur Ausgabe

Review Article

Inflammatory Nodules Following Soft Tissue Filler Use: A Review of Causative Agents, Pathology and Treatment Options

Evidence-Based Review

Treatment of Melasma with Topical Agents, Peels and Lasers: An Evidence-Based Review

Original Research Article

Prevalence of Metabolic Syndrome in Behçet Disease: A Case-Control Study in Turkey

Review Article

Barrier Repair Therapy in Atopic Dermatitis: An Overview

Short Communication

Efficacy, Tolerability and Consumer Acceptability of Terbinafine Topical Spray versus Terbinafine Topical Solution: A Phase IIa, Randomised, Observer-Blind, Comparative Study

Review Article

Burden of Disease: Psoriasis and Psoriatic Arthritis

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise